---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-021231"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T00:49:24.131006+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience Q3 net product sales down 18% YoY to $406K; net loss widens to $876K

## Summary
- Net product sales $406K in Q3 FY2023 vs $497K prior year, down 18% on decreased distribution sales.
- Q3 net loss $876K vs $760K prior year; net loss per share flat at ($0.01).
- Nine-month net product sales $1.27M vs $1.41M; net loss $2.93M vs $2.26M prior year.
- CEO cites key distributor downturn; food division sales partially offset; new sales program initiated.

## SEC filing metadata
- accession: 0001493152-23-021231
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/0001493152-23-021231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-021231
- JSON: https://secwatch.observer/filing/0001493152-23-021231.json
- Plain text: https://secwatch.observer/filing/0001493152-23-021231.txt

## Key facts
- Earnings Releases
  PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2023 results: revenue $406,000, net income $876,000, EPS ($0.01).
  - Period: the fiscal third quarter ended April 30, 2023
  - Revenue: $406,000
  - Net income: $876,000
  - EPS: ($0.01)
  - Result: reported results
  source text: Net product sales were $406,000 and $497,000 for the fiscal third quarters ended April 30, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/0001493152-23-021231-index.htm
- Earnings Releases
  PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2023 results: revenue $1,269,000, net income $2,929,000, EPS ($0.03).
  - Period: the nine months ended April 30, 2023
  - Revenue: $1,269,000
  - Net income: $2,929,000
  - EPS: ($0.03)
  - Result: reported results
  source text: Net product sales were $1,269,000 and $1,409,000 for the nine months ended April 30, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/0001493152-23-021231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.